Caspian Journal of Internal Medicine
1
Caspian J Intern Med
Medical Sciences
http://caspjim.com
1
admin
2008-6164
2008-6172
8
10.22088/cjim
14
8888
13
en
jalali
1395
1
1
gregorian
2016
4
1
7
2
online
1
fulltext
en
The acute lymphoblastic leukemia prognostic scoring whether it is possible by BCL-2, BAX gene promoter genotyping
Hematology
Hematology
Original Article
Original Article
<p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Background: </span></em></strong><span style="font-size: 10pt;">BCL-2 is the most important anti-apoptotic regulator and Bax is a pro-apoptotic protein. The status of these parameters or the ration of BCL-2 to BAX is important in malignant cell fate as well as normal cells.</span></span></p>
<p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Methods:</span></em></strong><span style="font-size: 10pt;"> Sixty-two ALL patients and 62 healthy sex-and age-matched controls were studied. After genotyping, the promoter region of the BAX and BCL-2 genes by RFLP-PCR method the patients were classified in nine prognostic groups, after that, the overall survival ratio of each score was compared with others pair-wise or between groups.</span></span></p>
<p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Results:</span></em></strong><span style="font-size: 10pt;"> The frequencies of the AA, AC, CC alleles of the BCL-2 C-938A polymorphism in patient group were 33 (53.23%), 18 (29.03%), 11 (17.74%), and in the control group were 13 (21.0%), 27 (43.5%), 22 (35.5%), respectively (P=0.003). Also, the frequencies of AA, AG, GG alleles of the BAX G-248A SNP were 15 (24.2%), 24 (38.7%), 23 (37.1%) in ALL group and 13 (21.0%), 25 (40.3%), 24 (38.7%) (p>0.05) in the control group. The survival time estimation and ratio were significantly different between different SNPs in BCL-2 (P=0.002).</span></span></p>
<p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Conclusion:</span></em></strong><span style="font-size: 10pt;"> </span><span style="font-size: 10pt;">These findings showed that the BCL-2 promoter region polymorphism is more reliable than BAX gene promoter polymorphism in any ALL scoring system. But the establishment of complete scoring system requires further more clinical and laboratory findings along with genetic polymorphisms is necessary</span></span></p>
Acute Lymphoblastic Leukemia, BAX, BCL2, Prognostic Scoring, Survival, Single Nucleotide Polymorphism
105
113
http://caspjim.com/browse.php?a_code=A-10-351-1&slc_lang=en&sid=1
Mozhgan
Moazami-Goudarzi
mgn_moazami@yahoo.com
10031947532846005334
10031947532846005334
No
Stem Cell Research Center, Tabriz University of Medical Science, Tabriz, Iran
Majid
Farshdousti-Hagh
mt09143163667@gmail.com
10031947532846005335
10031947532846005335
No
Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran
Abbasali
Hoseinpour-Feizi
pourfeizia@yahoo.com
10031947532846005336
10031947532846005336
No
Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran
Mehdi
Talebi
mt09143163667@yahoo.com
10031947532846005337
10031947532846005337
Yes
Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran
Ali-Akbar
Movassaghpour-Akbari
movassaghpour@tbzmed.ac.ir
10031947532846005338
10031947532846005338
No
Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran
Karim
Shams-Asanjan
kshams@ibto.ir
10031947532846005339
10031947532846005339
No
Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran
Jamal
Eyvazi-Ziyaee
eyvazij@yahoo.com
10031947532846005340
10031947532846005340
No
Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran
Morteza
Seifi
10031947532846005341
10031947532846005341
No
Department of Medical Genetics, University of Alberta, Alberta, Canada